CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Oct. 4, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 40,000 shares of...

CAMBRIDGE, Mass. & SALISBURY, United Kingdom --(BUSINESS WIRE)--Sep. 21, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will...

– US Site Initiations Ongoing – – Regulatory Submissions Complete for All Countries Participating in Trial – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 14, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery,...

– FDA End-of-Phase 2 Meeting for KVD900 Oral HAE Phase 3 Program Scheduled for This Month – – KVD824 Phase 2 KOMPLETE Clinical Trial Enrolling – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 9, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 2, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 43,000 shares of...

– KVD824 Clinical Trial Regulatory Approvals in Canada , Australia , and the UK – – Response Submitted to FDA on IND Requests for KVD824 Phase 2 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Aug. 23, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Aug. 9, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 20,000 shares of...

– FDA End-of-Phase 2 Meeting on KVD900 Oral HAE Phase 3 Program Scheduled for Late Q3 2021 – – FDA Response Submission for KVD824 Phase 2 Clinical Hold Expected Q3 2021 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 13, 2021-- KalVista Pharmaceuticals, Inc....

– Phase 2 data for KVD900 in late-breaking session at European Academy of Allergy and Clinical Immunology (EAACI) Congress – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 12, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 28, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced acceptance of multiple...